Hydroxychloroquine, Interleukin-6 Receptor Antagonists and Corticoid Treatments of Acute COVID-19 Infection: Psychiatric Symptoms and Mental Disorders 4 Months Later.

IF 2.4 4区医学 Q3 NEUROSCIENCES

Clinical Psychopharmacology and Neuroscience Pub Date : 2022-11-30 DOI:10.9758/cpn.2022.20.4.762

Matthieu Gasnier, Walid Choucha, David Montani, Nicolas Noël, Céline Verstuyft, Francois Radiguer, Xavier Monnet, Laurent Becquemont, Emmanuelle Corruble, Romain Colle

{"title":"Hydroxychloroquine, Interleukin-6 Receptor Antagonists and Corticoid Treatments of Acute COVID-19 Infection: Psychiatric Symptoms and Mental Disorders 4 Months Later.","authors":"Matthieu Gasnier, Walid Choucha, David Montani, Nicolas Noël, Céline Verstuyft, Francois Radiguer, Xavier Monnet, Laurent Becquemont, Emmanuelle Corruble, Romain Colle","doi":"10.9758/cpn.2022.20.4.762","DOIUrl":null,"url":null,"abstract":"Objective: Psychiatric symptoms and mental disorders are common after Coronavirus Disease-19 (COVID-19). Some drugs used to treat acute COVID-19 have psychiatric side effects. We assessed the psychiatric symptoms and mental disorders of patients treated for acute COVID-19 with hydroxychloroquine (HCQ), interleukin-6 receptor antagonists (anti-IL-6), and corticoids (CTC).Methods: We evaluated 177 patients in a day hospital 4 months after acute infection.Results: In a multivariate analysis, HCQ was associated with significant anxiety symptoms (odds ratio [OR] = 5.9, 95% confidence interval [95% CI] = 1.8-20.0, p = 0.003) and mental disorders (OR = 4.1, 95% CI = 1.2-13.9, p = 0.02). In a bivariate analysis with propensity matched cohorts, HCQ was associated with significant anxiety symptoms (9 patients [50.0%] with significant symptoms in the HCQ group versus 15 [20.1%] in the control group, OR = 3.8, 95% CI = 1.3-11.3, p = 0.01). Anti-IL-6 and CTC were not associated with significant psychiatric symptoms or mental disorders.Conclusion: We recommend monitoring psychiatric symptoms, especially anxiety, in patients treated with HCQ during COVID-19 infection. Further studies with larger samples and prospective assessments are needed to confirm our results.","PeriodicalId":10420,"journal":{"name":"Clinical Psychopharmacology and Neuroscience","volume":"20 4","pages":"762-767"},"PeriodicalIF":2.4000,"publicationDate":"2022-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/32/14/cpn-20-4-762.PMC9606425.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Psychopharmacology and Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.9758/cpn.2022.20.4.762","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 1

Abstract

Objective: Psychiatric symptoms and mental disorders are common after Coronavirus Disease-19 (COVID-19). Some drugs used to treat acute COVID-19 have psychiatric side effects. We assessed the psychiatric symptoms and mental disorders of patients treated for acute COVID-19 with hydroxychloroquine (HCQ), interleukin-6 receptor antagonists (anti-IL-6), and corticoids (CTC).

Methods: We evaluated 177 patients in a day hospital 4 months after acute infection.

Results: In a multivariate analysis, HCQ was associated with significant anxiety symptoms (odds ratio [OR] = 5.9, 95% confidence interval [95% CI] = 1.8-20.0, p = 0.003) and mental disorders (OR = 4.1, 95% CI = 1.2-13.9, p = 0.02). In a bivariate analysis with propensity matched cohorts, HCQ was associated with significant anxiety symptoms (9 patients [50.0%] with significant symptoms in the HCQ group versus 15 [20.1%] in the control group, OR = 3.8, 95% CI = 1.3-11.3, p = 0.01). Anti-IL-6 and CTC were not associated with significant psychiatric symptoms or mental disorders.

Conclusion: We recommend monitoring psychiatric symptoms, especially anxiety, in patients treated with HCQ during COVID-19 infection. Further studies with larger samples and prospective assessments are needed to confirm our results.

查看原文本刊更多论文

羟氯喹、白细胞介素-6受体拮抗剂和皮质激素治疗急性COVID-19感染:4个月后精神症状和精神障碍

目的:新型冠状病毒病-19 (COVID-19)后常见精神症状和精神障碍。一些用于治疗急性COVID-19的药物有精神方面的副作用。我们评估了羟氯喹(HCQ)、白细胞介素-6受体拮抗剂(抗il -6)和皮质激素(CTC)治疗急性COVID-19患者的精神症状和精神障碍。方法:对177例急性感染后4个月住院的患者进行评价。结果:在多因素分析中，HCQ与显著的焦虑症状(比值比[OR] = 5.9, 95%可信区间[95% CI] = 1.8-20.0, p = 0.003)和精神障碍(OR = 4.1, 95% CI = 1.2-13.9, p = 0.02)相关。在倾向匹配队列的双变量分析中，HCQ与显著焦虑症状相关(HCQ组有9例[50.0%]患者有显著焦虑症状，对照组有15例[20.1%]，OR = 3.8, 95% CI = 1.3-11.3, p = 0.01)。抗il -6和CTC与显著的精神症状或精神障碍无关。结论:我们建议在COVID-19感染期间监测HCQ患者的精神症状，特别是焦虑。需要更大样本的进一步研究和前瞻性评估来证实我们的结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Psychopharmacology and Neuroscience NEUROSCIENCESPHARMACOLOGY & PHARMACY-PHARMACOLOGY & PHARMACY

CiteScore

4.70

自引率

12.50%

发文量

期刊介绍： Clinical Psychopharmacology and Neuroscience (Clin Psychopharmacol Neurosci) launched in 2003, is the official journal of The Korean College of Neuropsychopharmacology (KCNP), and the associate journal for Asian College of Neuropsychopharmacology (AsCNP). This journal aims to publish evidence-based, scientifically written articles related to clinical and preclinical studies in the field of psychopharmacology and neuroscience. This journal intends to foster and encourage communications between psychiatrist, neuroscientist and all related experts in Asia as well as worldwide. It is published four times a year at the last day of February, May, August, and November.